Inotiv Executive and Leadership Team

Robert Leasure, the Chief Executive Officer & President at Inotiv, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the integration of scientific capabilities across the drug discovery continuum, Leasure ensures that the company maintains a competitive edge in the contract research market. This leadership role involves managing high-level relationships with stakeholders and driving the expansion of research model supply chains across North American markets. By prioritizing attentive and decisive service, Leasure fosters a culture of operational excellence that supports client programs from initial discovery through investigational new drug stages. Robert Leasure maintains a focus on delivering high-quality, on-time data to ensure regulatory success for all partners. Through consistent oversight of organizational performance, Leasure secures the financial health and market reputation of the firm while navigating complex industry requirements.

Beth Taylor, the Executive Vice President & Chief Financial Officer at Inotiv, manages the financial health, capital allocation, and fiscal planning for the entire organization. Overseeing the budgeting process and financial reporting, Taylor ensures that the company maintains the resources necessary to invest in world-class scientific talent and infrastructure. This leadership role involves analyzing market trends to support strategic growth initiatives and ensuring compliance with all financial regulations. By optimizing the cost structure and revenue streams, Taylor drives the long-term sustainability of the business model. Beth Taylor maintains a focus on transparency and investor relations, which builds confidence in the company's ability to deliver consistent value. Through the management of fiscal operations, Taylor supports the broader mission of providing high-quality research services, ensuring that the firm remains well-positioned to handle the complexities of the pharmaceutical development landscape.

Greg Beattie, the Chief Operating Officer at Inotiv, manages the daily execution of scientific services and operational workflows across all research facilities. Overseeing the complex logistics of critical research model supply, Beattie ensures that the company meets rigorous quality standards for rodents, rabbits, and nonhuman primates. This leadership role involves optimizing laboratory throughput and streamlining the transition of projects from discovery to IND submission. By implementing efficient resource allocation strategies, Beattie drives the operational scale necessary to support diverse client needs across international markets. Greg Beattie maintains a focus on operational consistency and data integrity, which remains central to the company's reputation for excellence. Through the coordination of cross-functional teams, Beattie ensures that every program receives the necessary attention to meet strict project timelines and regulatory expectations, ultimately enhancing the overall service delivery model.

Alison Bendele, the Founder and President of Bolder BioPATH at Inotiv, leads the specialized pathology and pharmacology services that form a core component of the company's research offerings. Overseeing the scientific direction of the Bolder BioPATH division, Bendele ensures that clients receive expert analysis and high-quality data for their drug discovery programs. This leadership role involves managing specialized laboratory teams and maintaining the high standards of scientific rigor required for IND-enabling studies. By integrating advanced pathology techniques into the broader service continuum, Bendele drives the company's ability to provide deep scientific insights. Alison Bendele maintains a focus on innovation and technical accuracy, which remains essential for the success of complex research projects. Through the leadership of this specialized unit, Bendele contributes to the company's reputation for delivering superlative experiences and reliable results to pharmaceutical partners.

Lizanne Muller, the Group President, RMS at Inotiv, directs the operations and strategic growth of the Research Model Services division. Overseeing the production and distribution of critical research models, including rodents, rabbits, and nonhuman primates, Muller ensures that the company meets the high-demand requirements of the global research community. This leadership role involves managing the supply chain and maintaining the health and quality standards of all research models. By optimizing the operational efficiency of the RMS division, Muller drives the availability of essential resources for drug discovery and development. Lizanne Muller maintains a focus on regulatory compliance and animal welfare, which remains central to the company's impeccable regulatory history. Through the management of these critical assets, Muller supports the broader mission of providing the foundational tools necessary for successful scientific investigation and pharmaceutical advancement.

Becky Dolliver, the Chief Information Officer at Inotiv, architects the digital infrastructure required to support advanced scientific research and data management. Overseeing the implementation of secure, scalable technology platforms, Dolliver ensures that all research data remains accurate, accessible, and compliant with global regulatory standards. This leadership role involves integrating sophisticated software solutions that facilitate seamless communication between laboratory scientists and external clients. By modernizing the technological framework, Dolliver drives improvements in data delivery speed and analytical precision. Becky Dolliver maintains a focus on cybersecurity and system reliability, which protects the integrity of sensitive drug discovery information. Through the strategic deployment of enterprise-wide IT initiatives, Dolliver supports the company's mission to provide a superlative experience for every client, ensuring that the digital environment remains as robust as the scientific capabilities provided by the organization.

Jeff Krupp, the Chief Human Resources Officer at Inotiv, directs the talent acquisition, employee development, and organizational culture initiatives. Overseeing the recruitment of world-class scientists and technical staff, Krupp ensures that the company retains the expertise required to support complex drug discovery projects. This leadership role involves designing performance management systems that align individual contributions with the company's overarching mission of scientific excellence. By fostering an environment of professional growth and engagement, Krupp drives the retention of top-tier talent across all regional operations. Jeff Krupp maintains a focus on building a diverse and inclusive workforce that reflects the global nature of the pharmaceutical industry. Through the implementation of strategic human capital programs, Krupp ensures that the organization possesses the human resources necessary to maintain its reputation for attentive, decisive service and high-quality data delivery.